Summary Modulation of nucleic acid antimetabolite cytotoxicity by preformed purines and pyrimidines may not only complicate the interpretation of drug sensitivity tests and other in vitro studies but also adversely affect treatment in vivo. Previously we reported that in a lymphocyte clonal assay, thymidine and hypoxanthine released from dead or damaged cells reduced methotrexate cytotoxicity. We now report that the nucleoside transport inhibitor dipyridamole (DP), at l.O jiM, abolished 3H-thymidine uptake into PHA stimulated lymphocytes, potentiated methotrexate cytotoxicity and reversed modulation of methotrexate cytotoxicity by exogenous thymidine and hypoxanthine. Normal growth of lymphocytes at high density was unaffected by 1.0-5.0jM dipyridamole, while growth at low densities was only slightly reduced. Hydroxynitrobenzylthioguanosine (555) was a less potent inhibitor of 3H-thymidine uptake and was toxic to normal lymphocytes at concentrations inhibiting 3H-thymidine uptake. Nucleoside transport inhibitors isolate the cellular effects of nucleic acid antimetabolites, and provide a tool to study mechanisms of antifolate cytotoxicity.
Inhibition of dihydrofolate reductase by methotrexate (MTX) limits synthesis of reduced folates, which are necessary cofactors in de novo purine and pyrimidine biosynthesis. It has long been recognised that MTX cytotoxicity may be modulated by the salvage of preformed purines and pyrimidine nucleosides (Taylor & Tattersall, 1981; Howell et al., 1981; Piper et al., 1983) .
Nucleosides enter cells via a single high affinity transporter with broad specificity and multiple forms (Plagemann & Wohlhueter, 1984) . Their transport can be inhibited by a variety of membrane active drugs such as cytochalasin B (Plagemann & Estersen, 1972) and colchicine (Mizel & Wilson, 1972) as well as by structural analogues of nucleosides such as dipyridamole (DP). DP, which inhibits adenosine, uridine and thymidine (TdR) uptake in human tumour cell lines (Bastida et al., 1985) , has been used to study nucleoside transport and accumulation in the murine cell lines L1210 and P388 (Plagemann & Wohlhueter, 1985) and in the human colon carcinoma cell line HCT-8 (Sobrero et al., 1985) . DP has also been reported to enhance MTX toxicity in L1210 cells in vitro and more recently in HCT116 cells (Van Mouwerik et al., 1987) . In addition DP increases the sensitivity of the human colonic cell line VAC05 to the purine antimetabolite acivicin (Fischer et al., 1984) . Nucleoside transport is also strongly inhibited by compounds derived from 9-fl-D-ribofuranosylpurine where the S, 0 or N atoms at the purine 6 position have a variety of arylalkyl group additions (Brajeswar et al., 1975) .
We have previously reported that cytotoxicity of MTX in a lymphocyte clonal assay was influenced by salvage of preformed nucleosides which accumulated in the culture medium and particularly when high cell densities were used (Hughes et al., 1988) . We postulated that nucleosides derived from the catabolism of nucleic acid from dead and dying cells were released into the culture medium.
Release of nucleosides from damaged cells becomes particularly relevant when large numbers of cells must be screened in order to detect very rare variants, e.g. in chemosensitivity testing and mutation assays. It is also potentially important in studies of the mechanisms involved in antimetabolite cytotoxicity. We now report a series of experiments investigating the effect of two nucleoside transport inhibitors, DP and 555 (6-(2-hydroxy-5-nitrobenzyl)-thioguanosine) (Brajeswar et al., 1975) For TdR uptake experiments mononuclear cells were set up initially in flask cultures at 1 x 106 cellsml-l and stimulated with phytohaemagglutinin (PHA) (1 jg ml-I culture) for 3-4 days. The remaining viable PBLs were diluted to 2 x 105 cells ml -using the above medium but containing interleukin-2 (IL-2) (10 half-maximal units (HMU) ml-1 culture) as well as PHA. This latter procedure was then repeated every 3-4 days. In this way PBLs could be maintained in log growth for up to 21 days.
For cloning experiments an aliquot of freshly isolated mononuclear cells at 1-2 x 106 cells was irradiated with 5,000cGy (60Coy-rays, room temperature) for use as feeder cells while PHA (1 jg ml -culture) was added to target cells. (Taswell, 1981) .
Thymidine uptake In a series of experiments 1-2x 106 exponentially growing PBLs were set up in 1 ml NM or DM cultures in duplicate at 37°C and pre-incubated for 30 min with or without added drug (dipyridamole, 0.5-20OM; or 555, 0.1-5.0 yM). 3H-TdR (specific activity 2,000 Cimol-') was then added (to give 1 gM TdR) and cells were harvested immediately or at intervals over a 60 min period by centrifugation at 4°C. The pellet was washed three times with ice-cold Dulbecco's phosphate buffered saline, and then digested with 3M NaOH (700C, 30min), acidified with 2N HCI and the radioactivity determined by liquid scintillation counting. Control cultures, cooled to 4°C for 30 min before and after 3H-TdR addition, were also studied.
Results

3H-Thymidine uptake
The effect of a range of concentrations of either DP or 555 on TdR uptake into PBLs cultured for 7-14 days was studied. 555 (0.1-5.0 /iM) reduced 3H-TdR uptake in a concentration dependent manner (Figure 1) . DP was more potent than 555, and at concentrations > 1 pM, 3H-TdR uptake at 37°C was reduced to that of control cells kept at 40C. (Figure 3a) . DP 1.0-S.OpM also potentiated MTX cytotoxicity (Figure 3b) . (1.0 uM) maintained a substantial level of growth in the presence of 100pM MTX (MTH) (Figure 4 ). The addition of 0.1 /uM 555 reduced this level of growth while 1.OMm 555 or 1.0-5.0,Mm DP completely inhibited it. However, in the absence of TdR, Hx and MTX (MTH), 0.1 Mm 555 inhibited normal growth and 1.OMm 555 was lethal. DP, 1.OpM, had no effect on growth in DM at these cell densities in the absence of MTX while 5.0pM DP reduced it slightly.
Discussion
The studies reported here demonstrate that both DP and 555 potentiate MTX cytotoxicity in PBLs in vitro. DP, I.OpM, abolished 3H-TdR uptake, potentiated MTX cytotoxicity and reversed TdR modulation of MTX cytotoxicity in stimulated PBLs (Figures 1, 3b and 4, respectively) . DP alone, up to 5.0 Mm, did not affect PBL growth at high cell density and only slightly decreased growth when cells were plated at lower densities (Figure 4) . 6-(2-hydroxy-5-nitrobenzyl)thioguanosine (555) potentiated MTX cytotoxicity (Figure 3c ) but was itself cytotoxic at concentrations which inhibited TdR uptake. Under these culture conditions 555 was a less potent inhibitor of TdR uptake in PBLs than DP, with > 5.0 Mm 555 being required. (Figure 2 ) or low density, and particularly at low density in medium with dialysed serum (Figure 4) . As the concentration of 555 which inhibited TdR uptake was at least 10 times greater than that which affected PBL growth, we conclude that its cytotoxicity is probably unrelated to TdR transport inhibition.
In cell culture the levels of exogenous purines and pyrimidines are greatly influenced by the serum used (Sobrero & Bertino, 1986; Piper et al., 1983 ). In addition nucleosides may be released into the culture medium from damaged cells (Hughes et al., 1988) . Figure 4 illustrates that DP reversed the TdR modulation of MTX cytotoxicity and is therefore a practical alternative to utilising dialysed serum when large numbers of cells are being screened, as in chemosensitivity testing. DP and other nucleoside transport inhibitors may also help define the cytotoxic mechanisms of antimetabolites such as MTX. DP is to be preferred to 555 since 555 is growth inhibitory by itself.
Potentiation of antimetabolite cytotoxicity by DP or other nucleoside transport inhibitors has relevance in vivo. TdR and Hx are present in plasma samples from normal subjects and cancer patients (Howell et al., 1981) . Regional variations in nucleoside and base concentrations have been reported in vivo, e.g. substantially greater levels of hypoxanthinexanthine being detected in bone marrow than in peripheral plasma . Anoxic cell death in avascular areas of a tumour may increase nucleoside and base levels locally. The relative activities of the rate-limiting enzymes of the pyrimidine de novo and salvage pathways are increased in neoplastic liver cells compared with normal cells (Weber, 1983) . Moreover, Weber (1983) has suggested that agents such as DP, in combination with the appropriate antimetabolite, may be effective for drug refractory tumours like colon cancer, because of their very active salvage pathways. Oral DP and low dose oral MTX showed some antitimour activity in lung and breast cancer patients in a phase I study (Subar et al., 1986) , but the combination was ineffective in a phase II trial in patients with advanced colorectal carcinoma (Wadler et al., 1987) . The authors postulated that this was due to incomplete inhibition of nucleoside salvage by oral DP and advocated further studies using i.v. infusion of DP. The possible reduction in antimetabolite cytotoxicity due to metabolite salvage is a compelling reason for further investigation of the potential role for nucleoside transport inhibitors, such as DP, in modulating nucleic acid antimetabolite drug action in vivo.
